CMS Invests
Technology Investor, Options Trader, Finance at Kalshi
A full scale-up co-packaged optics ramp could perhaps lift Lumentum 2-3x over 3-4 years. Lumentum is not worth anywhere near $1 trillion. x.comÂ
A buyout would devalue Lumentum's work and be the worst outcome for shareholders when demand and investor interest are strong. Lumentum has been exceeding demand requirements and doing exceptionally well on its own, so it is better off independent; if the rumors are rejected, its rally should continue higher. x.comÂ
Lumentum is a great business, but at $954 its risk/reward is not attractive. Applying 30x to fiscal 2028 non-GAAP EPS of $40 gives a 2027 price target of $1,200, about 26% upside, or roughly 15% after adjusting for execution, financial, technology and supply risks. Reaching it needs on-time manufacturing ramps, sustained pricing power and cash flow without excessive dilution. Lost pricing power plus slipping OCS or laser ramps would break the thesis; a significant dip would offer a better entry. … Show more
Lumentum's optics business is too valuable to sell for less than $2,000 a share, making a rumored Marvell takeover implausible. Lumentum is worth at least $2,000 a share now; a $120 billion purchase would consume about 60% of Marvell's roughly $200 billion market value, while a fair price would be closer to $160 billion in this view. x.com x.com x.comÂ
Lumentum's breakout to a record weekly close, up 15.3% and erasing five months of chop in one week, is backed by revenue growing 109% year over year rather than hype. x.comÂ
Lumentum requires paying up heavily for a company that is not yet making money. Revenue grew 109% year over year, but it trades at about 25 times annualized sales, and it is growing less than memory makers at ten times their valuation. @ZeekTyt cites Lumentum's CEO expecting to supply only about 30% of requested laser demand as CPO and NPO ramp in 2027, with balance around 2029-30. x.com x.comÂ
Lumentum's 109% year-on-year growth and sold-out capacity through 2029 make selling its AI optics exposure questionable. Bloomberg reported Marvell is in advanced talks to buy it; the appeal depends on the price, especially when holders of an $80 billion Lumentum would become holders of a $320 billion-plus Marvell growing 37%. x.comÂ
Owning Lumentum's laser fab could secure Marvell's FY28 supply and hedge its DSP franchise as optical links shift to CPO. The rumored deal's strategy makes sense, but short-term pain is likely: at a 30% premium, roughly $17.5B in new debt and the rest in stock, rough math puts EPS dilution near 15%. It turns accretive only if Lumentum outgrows Marvell at today's guided rates for five or six more quarters, which looks achievable while the laser shortage lasts. x.com x.com x.comÂ
The photonics-as-AI-bottleneck claim has faded, leaving Lumentum facing more pain before the theme recovers. A large December options node sits at $600; the stock bot targets downside at $650 and $595, with $581 a possible liquidity sweep where smart money would buy instead of rushing in at $650 or $630. Most photonics companies will likely never come back. x.comÂ
Lumentum's setup front-runs big money: price undercut a level and is looking to form a higher low, with order-book support at $1,060. Option pricing points to a $1,090 target. x.com x.comÂ